This brand name is authorized in United States
The drug NUPLAZID contains one active pharmaceutical ingredient (API):
|
1
Pimavanserin
UNII NA83F1SJSR - PIMAVANSERIN TARTRATE
|
|
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The mechanism of action of is unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| NUPLAZID Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 63090-100, 63090-170, 63090-340 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
